About: Lanreotide autogel therapy in patients with acromegaly - current role and perspectives for the future     Goto   Sponge   NotDistinct   Permalink

An Entity of Type : http://linked.opendata.cz/ontology/domain/vavai/Vysledek, within Data Space : linked.opendata.cz associated with source document(s)

AttributesValues
rdf:type
Description
  • Lanreotide Autogel, a long-acting somatostatin analogue, normalizes growth hormone and insulin-like growth factor I levels in about 50% of patients with acromegaly and causes tumour volumes to shrink by more than 20% in 72-85% of them. It has the advantage of being available in convenient pre-filled syringe and it can be injected subcutaneously by patients or their care-givers/partners. The efficacy of lanreotide can be increased by combination with dopamine agonists.
  • Lanreotide Autogel, a long-acting somatostatin analogue, normalizes growth hormone and insulin-like growth factor I levels in about 50% of patients with acromegaly and causes tumour volumes to shrink by more than 20% in 72-85% of them. It has the advantage of being available in convenient pre-filled syringe and it can be injected subcutaneously by patients or their care-givers/partners. The efficacy of lanreotide can be increased by combination with dopamine agonists. (en)
Title
  • Lanreotide autogel therapy in patients with acromegaly - current role and perspectives for the future
  • Lanreotide autogel therapy in patients with acromegaly - current role and perspectives for the future (en)
skos:prefLabel
  • Lanreotide autogel therapy in patients with acromegaly - current role and perspectives for the future
  • Lanreotide autogel therapy in patients with acromegaly - current role and perspectives for the future (en)
skos:notation
  • RIV/00064165:_____/10:6464!RIV11-MZ0-00064165
http://linked.open...avai/riv/aktivita
http://linked.open...avai/riv/aktivity
  • V
http://linked.open...iv/cisloPeriodika
  • 2
http://linked.open...vai/riv/dodaniDat
http://linked.open...aciTvurceVysledku
http://linked.open.../riv/druhVysledku
http://linked.open...iv/duvernostUdaju
http://linked.open...titaPredkladatele
http://linked.open...dnocenehoVysledku
  • 267872
http://linked.open...ai/riv/idVysledku
  • RIV/00064165:_____/10:6464
http://linked.open...riv/jazykVysledku
http://linked.open.../riv/klicovaSlova
  • Acromegaly; pituitary adenoma; somatostatin analogues; lanreotide (en)
http://linked.open.../riv/klicoveSlovo
http://linked.open...odStatuVydavatele
  • GB - Spojené království Velké Británie a Severního Irska
http://linked.open...ontrolniKodProRIV
  • [69177C47DD68]
http://linked.open...i/riv/nazevZdroje
  • European Endocrinology
http://linked.open...in/vavai/riv/obor
http://linked.open...ichTvurcuVysledku
http://linked.open...cetTvurcuVysledku
http://linked.open...UplatneniVysledku
http://linked.open...v/svazekPeriodika
  • 6
http://linked.open...iv/tvurceVysledku
  • Marek, Josef
issn
  • 1758-3772
number of pages
Faceted Search & Find service v1.16.118 as of Jun 21 2024


Alternative Linked Data Documents: ODE     Content Formats:   [cxml] [csv]     RDF   [text] [turtle] [ld+json] [rdf+json] [rdf+xml]     ODATA   [atom+xml] [odata+json]     Microdata   [microdata+json] [html]    About   
This material is Open Knowledge   W3C Semantic Web Technology [RDF Data] Valid XHTML + RDFa
OpenLink Virtuoso version 07.20.3240 as of Jun 21 2024, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (126 GB total memory, 58 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software